From The Hill
Former official David Mansdoerfer argues that bureaucratic delays at the FDA threaten American leadership in the growing regenerative medicine sector and give international competitors like China a strategic advantage.
From The Hill
Former official David Mansdoerfer argues that bureaucratic delays at the FDA threaten American leadership in the growing regenerative medicine sector and give international competitors like China a strategic advantage.
Leave a Reply